Full Breakdown
Sanofi-Regeneron Expand Immunology Alliance in $8 B Deal
By Drooid · · How we work
Expanded Partnership Overview
On Oct 1, Sanofi and Regeneron announced an expanded collaboration to co-develop and co-commercialize four long-acting antibody therapies targeting type-2 inflammation pathways. Sanofi will pay Regeneron $1 billion upfront with up to $7 billion in milestone payments tied to development, regulatory and commercial milestones. The companies will share research and development costs equally and split future profits 50:50 worldwide. Regeneron will lead the scientific work; Sanofi will handle global sales. The agreement also settles prior litigation over Dupixent data sharing.
Background & Context
The partnership dates to 2003 and has produced Dupixent (dupilumab), an IL-4R?-targeting antibody that generated €44 billion in 2025 sales, representing 36 % of Sanofi’s total revenue. Dupixent’s U.S. patent expires in 2031, with broader protection extending to 2045. Both firms seek next-generation antibodies that retain Dupixent’s efficacy while offering longer dosing intervals.
Data & Statistics
| Item | Detail |
|---|---|
| Up-front payment | $1 billion |
| Potential total value | $8 billion (including milestones) |
| New antibodies | 4 |
| Lead candidate | REGN20423 – IL-13 antibody, Phase 1 for atopic dermatitis |
| Timeline for other three | Expected human testing in 2027 |
| Dupixent 2025 global sales | $18.3 billion |
| Patent expiry (U.S.) | 2031 |
Official Statements & Responses
Regeneron’s chief scientific officer, George Yancopoulos, highlighted the combination of Regeneron’s discovery platform with Sanofi’s commercial reach. Regeneron CEO Leonard Schleifer noted that the expanded alliance builds on a historically productive partnership and aims to bring “promising new long-acting antibodies” to patients faster. Both companies confirmed that the existing Dupixent profit-sharing arrangement remains unchanged.
Criticism & Opposition
Markus Manns, portfolio manager at Union Investment, questioned the $1 billion upfront cost given the early-stage nature of the assets.
Verbatim Quotes
- “Mutual trust will be the guiding principle in this extended relationship,” — Belen Garijo, Sanofi’s CEO
- “By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology,” — George Yancopoulos
Timeline
- Oct 1 – Announcement and settlement of prior litigation.
- 2025 – Dupixent reaches $18.3 billion in global sales; U.S. patent set to expire in 2031.
- 2025-2026 – REGN20423 progresses through Phase 1; first $1 billion milestone payable upon reaching late-stage testing.
- 2027 – Expected start of human trials for the three pre-clinical antibodies.
- 2029 – Projected readouts for lunsekimig Phase 3 COPD trials, after which Regeneron may exercise its option to include the drug in the alliance.
What’s Next
The immediate focus will be the Phase 1 outcomes for REGN20423 and preparation for the 2027 clinical launches of the remaining candidates. Milestone payments to Regeneron will be triggered as each antibody meets predefined development and regulatory benchmarks.